| Gene symbol | ITGA4 | Synonyms | CD49D, IA4 | Type of gene | protein-coding |
| Chromosome | 2 | Map location | 2q31.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | integrin subunit alpha 4 | ||||
| GTO ID | GTC0622 |
| Trial ID | 2006-004736-79 |
| Disease | Multiple Sclerosis |
| Altered gene | CD49d |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ATL1102 |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis. |
| Year | 2007 |
| Country | Czechia |
| Company sponsor | Antisense Therapeutics Ltd. |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||